Literature DB >> 2856460

Onset of action of captopril, enalapril, enalaprilic acid and lisinopril in normal man.

P F Semple1, A M Cumming, P A Meredith, J J Morton.   

Abstract

The effects of orally administered captopril, enalapril and lisinopril on plasma concentrations of angiotensin converting enzyme (ACE), angiotensin II (ANGII) and renin (PRC) were studied over a period of 6 hours in 6 normal subjects. A further 4 subjects received intravenous enalapril and enalaprilic acid (enalaprilat). Captopril (25 mg) by mouth caused a fall in pANGII that reached a nadir 30 to 40 minutes after administration but an effect was hardly apparent after 6 hours. Enalapril (10 mg) by mouth had less marked effects on pACE and pANGII with a decline in levels first apparent 1 hour after administration and the lowest levels reached between 3 and 6 hours. Lisinopril (10 mg) produced a progressive fall in pACE and pANGII from 1 hour to reach the lowest values 6 hours after treatment. Intravenous enalaprilat (5 mg) produced an immediate sustained fall in both pACE and pANGII but intravenous enalapril (7 mg) had a biphasic inhibitory effect.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2856460     DOI: 10.1007/bf02125832

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  18 in total

1.  The measurement of angiotensin-converting enzyme in subjects receiving captopril.

Authors:  J E Roulston; G A MacGregor
Journal:  N Engl J Med       Date:  1980-08-14       Impact factor: 91.245

2.  Measurement of plasma angiotensin II.

Authors:  J J Morton; D J Webb
Journal:  Clin Sci (Lond)       Date:  1985-04       Impact factor: 6.124

3.  A new class of angiotensin-converting enzyme inhibitors.

Authors:  A A Patchett; E Harris; E W Tristram; M J Wyvratt; M T Wu; D Taub; E R Peterson; T J Ikeler; J ten Broeke; L G Payne; D L Ondeyka; E D Thorsett; W J Greenlee; N S Lohr; R D Hoffsommer; H Joshua; W V Ruyle; J W Rothrock; S D Aster; A L Maycock; F M Robinson; R Hirschmann; C S Sweet; E H Ulm; D M Gross; T C Vassil; C A Stone
Journal:  Nature       Date:  1980-11-20       Impact factor: 49.962

4.  Pharmacokinetic properties of captopril after acute and chronic administration to hypertensive subjects.

Authors:  B Jarrott; O Drummer; R Hooper; A I Anderson; P J Miach; W J Louis
Journal:  Am J Cardiol       Date:  1982-04-21       Impact factor: 2.778

5.  Immediate and sustained hemodynamic and clinical improvement in chronic heart failure by an oral angiotensin-converting enzyme inhibitor.

Authors:  R Ader; K Chatterjee; T Ports; B Brundage; B Hiramatsu; W Parmley
Journal:  Circulation       Date:  1980-05       Impact factor: 29.690

6.  Comparison of captopril and enalapril in patients with severe chronic heart failure.

Authors:  M Packer; W H Lee; M Yushak; N Medina
Journal:  N Engl J Med       Date:  1986-10-02       Impact factor: 91.245

7.  Angiotensin II levels, hemodynamics, and sympathoadrenal function after low-dose captopril in heart failure.

Authors:  J Cleland; P Semple; P Hodsman; S Ball; I Ford; H Dargie
Journal:  Am J Med       Date:  1984-11       Impact factor: 4.965

8.  The physiological disposition and metabolism of enalapril maleate in laboratory animals.

Authors:  D J Tocco; F A deLuna; A E Duncan; T C Vassil; E H Ulm
Journal:  Drug Metab Dispos       Date:  1982 Jan-Feb       Impact factor: 3.922

9.  Factors related to first dose hypotensive effect of captopril: prediction and treatment.

Authors:  G P Hodsman; C G Isles; G D Murray; T P Usherwood; D J Webb; J I Robertson
Journal:  Br Med J (Clin Res Ed)       Date:  1983-03-12

10.  Clinical pharmacology of enalapril.

Authors:  W B Abrams; R O Davies; H J Gomez
Journal:  J Hypertens Suppl       Date:  1984-12
View more
  3 in total

Review 1.  Tissue and plasma angiotensin converting enzyme and the response to ACE inhibitor drugs.

Authors:  R J MacFadyen; K R Lees; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1991-01       Impact factor: 4.335

Review 2.  Lisinopril. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  S G Lancaster; P A Todd
Journal:  Drugs       Date:  1988-06       Impact factor: 9.546

3.  Comparison of captopril with enalapril in the treatment of heart failure: influence on hemodynamics and measures of renal function.

Authors:  K J Osterziel; R Dietz; K Harder; W Kübler
Journal:  Cardiovasc Drugs Ther       Date:  1992-04       Impact factor: 3.727

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.